The legal access landscape shifted meaningfully in April 2026 when the FDA removed both peptides from its Category 2 restricted list
BPC-157 has 30 subjects, one investigator, and no Phase III trial on any horizon
What it does is initiate a formal rulemaking process under the Federal Food, Drug, and Cosmetic Act in which the FDA must publish a proposed rule, accept public comment typically for 60 to 90 days and issue a final determination
These findings are encouraging, though more large-scale trials are needed
Learn more Location: Jakarta KJPP Susan Widjojo & Rekan is a part of the international property consultants and advisors network called VPC Asia Pacific
Then, at last years conference, he met Lee